Cigna earnings beat by $0.04, revenue topped estimates
Trill AB, a ten percent owner of DiaMedica Therapeutics Inc (NASDAQ:DMAC), reported purchasing 1,542,857 common shares of the company on July 23, 2025. The shares were bought at a price of $3.5, totaling approximately $5,399,999. The stock, which currently trades at $5.05, has shown strong momentum with a 20.81% gain in the past week. According to InvestingPro analysis, the company maintains a healthy balance sheet with more cash than debt and a robust current ratio of 8.02.
Following the transaction, Trill AB directly holds 6,764,465 DiaMedica Therapeutics shares. Jan Stahlberg, as the board member and sole owner of Trill AB, indirectly owns these shares and has the sole power to vote and dispose of them. With the company’s next earnings report due on August 6, investors seeking deeper insights can access comprehensive analysis and 10+ additional ProTips through InvestingPro’s detailed research reports.
In other recent news, DiaMedica Therapeutics Inc. has completed a $30.1 million private placement, issuing approximately 8.6 million common shares at $3.50 per share. The company plans to use the net proceeds of approximately $29.9 million to fund its clinical development programs focused on preeclampsia, fetal growth restriction, and acute ischemic stroke. Additionally, H.C. Wainwright has raised its price target for DiaMedica from $10 to $12, maintaining a Buy rating on the stock. This adjustment follows positive interim results from the company’s Phase 2 study of DM199 for preeclampsia treatment, which met pre-specified safety and efficacy endpoints. The study showed statistically significant reductions in blood pressure and improved uterine blood flow. Furthermore, a recent key opinion leader event highlighted DM199’s potential as a disease-modifying therapy for preeclampsia. Specialists expressed optimism, as the company expects topline results from the ongoing Phase 2 study between June and July 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.